FDA Peptide Tracker

Tirzepatide: live FDA regulatory status

Dual GIP/GLP-1 · GLP-1

The two signals

Plain-English verdict: green.

Regulatory status: 503A / shortage-exception pathway.

These two never collapse into one. Removal from a list is not the same as legal-to-compound, and neither is the same as available.

Availability at Peptós.LIFE

Available

What Tirzepatide is

A dual GIP/GLP-1 medicine with the strongest weight and metabolic trial data in the category.

Short version: the newest, most effective molecule in the metabolic class, with grade-A randomized human data behind it. Available compounded under a clinician, and, like all compounded medicines, not FDA-approved.

Tirzepatide hits two receptors instead of one, which is why its trial numbers lead the category. We lead with the path, the right dose, muscle preservation, and the graduation plan, not the molecule alone.

Why it sits in this category

Tirzepatide is tracked under GLP-1. Its regulatory status is 503A / shortage-exception pathway — a separate signal from whether you can actually get it today. We never collapse the two.

Available now through a clinician. Branded versions are FDA-approved; compounded tirzepatide is not FDA-approved and supply is constrained, eligibility is a clinical decision.

A dual agonist at both GIP and GLP-1 receptors, amplifying satiety and glycemic effects beyond a GLP-1 alone.

What it does — and what it does not do

What it does: Supports the largest average weight loss and metabolic improvement seen in randomized trials to date.

What it does not do: It is not a guaranteed result and not a substitute for the habits that keep the loss; compounded forms are not FDA-approved.

What would have to change

Next milestone on the regulatory path: 503B comments close — Jun 29, 2026. A favorable advisory (PCAC) vote is a recommendation that leads to rulemaking — not FDA approval, not authorization to compound, and not availability.

Evidence grade

Grade A — large randomized controlled trials (SURMOUNT / SURPASS). See our grading methodology for what each grade means.

What we still don't know: Head-to-head long-term outcome data is still maturing; compounded-formulation specifics differ from the studied branded product.

Regulatory timeline

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.

Primary source: FDA source record

See the full status board or this molecule's knowledge-base monograph.

Last updated July 26, 2026 · Peptós.LIFE · Not medical advice.